Flood J F, Cherkin A
Behav Neural Biol. 1986 Mar;45(2):169-84. doi: 10.1016/s0163-1047(86)90750-8.
Scopolamine-treated normal young human subjects exhibit memory dysfunctions analogous to those observed in demented patients. The dysfunctions are reversible by physostigmine but not by d-amphetamine which suggests that the memory impairment is specifically related to reduced cholinergic transmission caused by scopolamine. Scopolamine-induced amnesia has been proposed as a model for dementia where reduced cholinergic function is the suspected cause. We report seven experiments in young adult mice which examine scopolamine's effects on memory retention and whether its amnestic effects are specifically blocked by cholinergic agonists or cholinomimetics. Young adult mice were trained to avoid footshock in a T maze and their retention tested 1 week after training. Pretraining subcutaneous injection of scopolamine improved retention scores of "undertrained" mice at a dose of 0.01 mg/kg but impaired at a dose of 0.1 mg/kg. Post-training injection showed no effect at 0.01 mg/kg, enhanced retention scores at 0.1 mg/kg, and impaired at 1.0 mg/kg. The impairment by 1.0 mg/kg was blocked by injection 45 min post-training of each of two cholinergic drugs but was also counteracted by six drugs which act upon five other neural systems (catecholamine, serotonin, glycine, GABA, and hormonal). When scopolamine was injected 40 min pretraining, and each of eight drugs was injected immediately after training, the amnestic effect of scopolamine was only partially counteracted. This suggests that scopolamine impaired acquisition, in addition to some impairment of memory processing. This was confirmed by a direct study of acquisition rates of the avoidance response; 0.1 mg/kg of scopolamine impaired acquisition. The overall results indicate that pretraining administration of scopolamine impairs learning and to some degree memory processing. Counteracting scopolamine-induced amnesia, by either pretraining or post-training drug administration, is not specific to the cholinergic system.
东莨菪碱处理的正常年轻人类受试者表现出与痴呆患者中观察到的类似的记忆功能障碍。这些功能障碍可被毒扁豆碱逆转,但不能被右旋苯丙胺逆转,这表明记忆损害与东莨菪碱引起的胆碱能传递减少特别相关。东莨菪碱诱导的失忆已被提议作为痴呆症的模型,其中胆碱能功能降低被怀疑是病因。我们报告了七项在成年小鼠中的实验,这些实验研究了东莨菪碱对记忆保持的影响,以及其失忆作用是否被胆碱能激动剂或拟胆碱药特异性阻断。成年小鼠在T迷宫中接受训练以避免足部电击,并在训练1周后测试其记忆保持情况。训练前皮下注射东莨菪碱,剂量为0.01mg/kg时可提高“训练不足”小鼠的记忆保持分数,但剂量为0.1mg/kg时则会损害记忆保持。训练后注射,0.01mg/kg时无效果,0.1mg/kg时提高记忆保持分数,1.0mg/kg时则损害记忆保持。1.0mg/kg的损害可被两种胆碱能药物在训练后45分钟注射阻断,但也可被作用于其他五个神经系统(儿茶酚胺、血清素、甘氨酸、γ-氨基丁酸和激素)的六种药物抵消。当在训练前40分钟注射东莨菪碱,并在训练后立即注射八种药物中的每一种时,东莨菪碱的失忆作用仅被部分抵消。这表明东莨菪碱除了对记忆处理有一些损害外,还损害了习得。对回避反应习得率的直接研究证实了这一点;0.1mg/kg的东莨菪碱损害了习得。总体结果表明,训练前给予东莨菪碱会损害学习并在一定程度上损害记忆处理。通过训练前或训练后给药来抵消东莨菪碱诱导的失忆,并不特定于胆碱能系统。